Pervasis Therapeutics is a clinical stage company offering a broad portfolio of biologically active therapeutics.
Pervasis Therapeutics is a clinical stage company developing a broad portfolio of biologically active therapeutics. Building on its deep understanding of the specialized role that the endothelium plays in regulating natural healing and repair processes associated with disease, Pervasis is advancing groundbreaking new therapies to dramatically improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stents, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 15, 2008 | Series Unknown | $9.75M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Musket Research Associates | — | Series Unknown |